
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+4
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently undruggable targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDSTM platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects
Drug discovery,undruggable,pseudokinase,mid-size molecule,bi-functional compound,oncology,immuno-oncology,protein degrader,and targeted protein degradation
Fimecs, inc operates in the Pharmaceutical manufacturing industry.
Fimecs, inc's revenue is 11m - 100m
Fimecs, inc has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.